Intelligent Bio Solutions Achieves 94.1% Accuracy in Method Comparison Study, Following Positive PK Study Results
26. November 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
Intelligent Fingerprinting Drug Screening System on path to FDA 510(k) submission, expected in the fourth calendar quarter of 2024 INBS will include data from recent PK study alongside results of...
Intelligent Bio Solutions to Participate in the Noble Capital Markets’ 20th Annual Emerging Growth Equity Conference
21. November 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) (“INBS” or the “Company”), a medical technology company delivering intelligent, rapid, non-invasive testing...
Intelligent Bio Solutions Announces Positive Results of PK Study, a Key Milestone on Path to FDA 510(k) Submission
13. November 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
PK Study Successfully Demonstrates that Fingerprint Sweat Provides Reliable Sample for Drug Detection FDA 510(k) Clearance Would Enable the Introduction of INBS’ Technology to the US in 2025 NEW...
Intelligent Bio Solutions Reports Fiscal 2025 First Quarter Financial Results and Operational Highlights
07. November 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
Quarterly revenue increased 10% year-on-year and 20% quarter-on-quarter, marking four consecutive quarters of year-on-year growth Higher-margin, recurring cartridge revenue surpassed reader revenue...
Intelligent Bio Solutions Partners with B2i Digital to Amplify Investor Outreach
31. Oktober 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
Intelligent Bio Solutions has partnered with B2i Digital to execute an investor communications program.
Intelligent Bio Solutions Announces Preliminary Unaudited Fiscal 2025 First Quarter Revenue Results
29. Oktober 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
Unaudited quarterly revenue increased 10% year-on-year and 20% quarter-on-quarter Higher-margin, recurring cartridge revenue expected to surpass reader revenue as primary...
Intelligent Bio Solutions Celebrates One Year Anniversary of Enhanced Workplace Safety with London-Based Real-Estate Developer, Mount Anvil
24. Oktober 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
INBS announces one year of enhanced workplace safety with Mount Anvil following the integration of fingerprint drug testing.
Intelligent Bio Solutions Announces Adoption of its Non-Invasive Drug Screening Solution by Global Engineering Leader, Pyrotek
14. Oktober 2024 08:00 ET
|
Intelligent Bio Solutions, Inc.
NEW YORK, Oct. 14, 2024 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company offering non-invasive, rapid testing solutions,...
Intelligent Bio Solutions Partners with Spirit Group as Australian Distributor, Expanding Community Impact with Intelligent Fingerprinting Drug Testing Solution
09. Oktober 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
INBS announces its distribution partnership with Spirit Group, an Australian, Indigenous-owned marketing and consulting agency.
GPS Marine Adopts Intelligent Bio Solutions’ Fingerprint Drug Testing Technology to Boost Workplace Safety in Maritime Services
01. Oktober 2024 08:30 ET
|
Intelligent Bio Solutions, Inc.
INBS announces the addition of GPS Marine, a leading provider of marine construction and logistics services, to its growing number of customer accounts.